Gemelli Biotech is a pioneering company in the field of precision diagnostics for gastrointestinal (GI) diseases. The company focuses on leveraging cutting-edge biological discoveries related to the microbiome to develop non-invasive diagnostic tools. These tools enable clinicians to accurately detect scientifically validated biomarkers and provide optimal treatment for GI conditions such as Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), excess hydrogen sulfide, and post-infectious Irritable Bowel Syndrome (IBS).

Gemelli Biotech primarily serves healthcare providers, including gastroenterologists and general practitioners, who require precise diagnostic solutions to improve patient outcomes. The company operates in the healthcare diagnostics market, which is characterized by a growing demand for non-invasive and accurate diagnostic methods.

The business model of Gemelli Biotech revolves around the development and commercialization of its diagnostic tests. The company generates revenue by selling these diagnostic kits to healthcare providers and laboratories. Additionally, Gemelli Biotech may engage in partnerships with research institutions and pharmaceutical companies to further validate and expand its diagnostic offerings.

Gemelli Biotech's innovative approach not only enhances the accuracy of GI disease diagnosis but also contributes to personalized treatment plans, ultimately improving patient care and reducing healthcare costs.

Keywords: precision diagnostics, GI diseases, microbiome, biomarkers, non-invasive, SIBO, IMO, hydrogen sulfide, IBS, healthcare providers.